Additionally, one study of diagnosis-to-relapse FLT3-ITD patients demonstrated that XPO1 expression increased at time of relapse and inhibition of XPO1 with selinexor increased sensitivity to induction chemotherapy used for AML. Here, XPO1 is linked to acute myeloid leukemia.